Read Summary

The FDA’s decision stems from the review of a 5-year trial designed to evaluate cardiac risk with the weight-loss drug. “We believe that the risks of lorcaserin outweigh its benefits,” the FDA said.
News Alerts

Print Friendly, PDF & Email